In Brief: Penederm
This article was originally published in The Tan Sheet
Executive Summary
Penederm: Submits amendments to its NDAs for retinoic acid cream and gel products for treatment of acne to FDA, the company announces Jan. 3. FDA issued a "nonapprovable" letter to the company in April, one year after the NDA filings, citing manufacturing and control issues and the need for clarified clinical data. Penederm initiated a 90-day clinical trial on the side-effect profile of its products at the end of September, although FDA said it did not need the additional data. The dermatological company's retinoic acid products, which use a patented drug delivery technology, are marketed in Canada by PharmaScience under the trade name Vitinoin...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning